The application of cell-based assays (CBA) has clarified MOGAD diagnoses for patients who were previously categorized as anti–aquaporin-4 immunoglobulin G (AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD) (3). The gene discussed is AQP4; the disease is neuromyelitis optica.